Marathon Asset Management Ltd reduced its position in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,066,303 shares of the company's stock after selling 70,047 shares during the period. Marathon Asset Management Ltd owned about 0.62% of Envista worth $20,568,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. Amalgamated Bank lifted its holdings in Envista by 0.7% in the fourth quarter. Amalgamated Bank now owns 80,380 shares of the company's stock worth $1,551,000 after purchasing an additional 523 shares during the period. GAMMA Investing LLC lifted its position in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock worth $44,000 after buying an additional 538 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company's stock valued at $43,000 after buying an additional 728 shares in the last quarter. Huntington National Bank raised its holdings in Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company's stock valued at $38,000 after buying an additional 949 shares in the last quarter. Finally, Hudson Edge Investment Partners Inc. raised its holdings in Envista by 4.8% in the 4th quarter. Hudson Edge Investment Partners Inc. now owns 24,931 shares of the company's stock worth $481,000 after acquiring an additional 1,150 shares during the period.
Wall Street Analyst Weigh In
NVST has been the subject of a number of analyst reports. Wells Fargo & Company boosted their target price on shares of Envista from $20.00 to $21.00 and gave the company an "equal weight" rating in a research note on Thursday, February 6th. Mizuho initiated coverage on shares of Envista in a research note on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price target for the company. Piper Sandler lifted their price objective on shares of Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Morgan Stanley decreased their target price on Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. dropped their price target on Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $20.38.
Check Out Our Latest Stock Analysis on Envista
Envista Trading Down 2.2 %
Envista stock traded down $0.40 during mid-day trading on Thursday, hitting $17.84. The company's stock had a trading volume of 2,719,852 shares, compared to its average volume of 2,297,773. The company has a 50 day moving average of $20.27 and a 200-day moving average of $19.69. Envista Holdings Co. has a one year low of $15.15 and a one year high of $23.00. The stock has a market cap of $3.07 billion, a PE ratio of -2.75, a P/E/G ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.
Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, research analysts anticipate that Envista Holdings Co. will post 1 EPS for the current year.
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
